Fused Deposition Modeling (FDM) 3D Printed Tablets for Intragastric Floating Delivery of Domperidone

Abstract

The aim of this study was to explore the feasibility of fused deposition modeling (FDM) 3D printing to prepare intragastric floating sustained release (FSR) tablets. Domperidone (DOM), an insoluble weak base, was chosen as a model drug to investigate the potential of FSR in increasing its oral bioavailability and reducing its administration frequency. DOM was successfully loaded into hydroxypropyl cellulose (HPC) filaments using hot melt extrusion (HME). The filaments were then printed into hollow structured tablets through changing the shell numbers and the infill percentages. Physical characterization results indicated that the majority of DOM gradually turned into the amorphous form during the fabrication process. The optimized formulation (contain 10% DOM, with 2 shells and 0% infill) exhibited the sustained release characteristic and was able to float for about 10 h in vitro. Radiographic images showed that the BaSO4-labeled tablets were retained in the stomach of rabbits for more than 8 h. Furthermore, pharmacokinetic studies showed the relative bioavailability of the FSR tablets compared with reference commercial tablets was 222.49 ± 62.85%. All the results showed that FDM based 3D printing might be a promising way to fabricate hollow tablets for the purpose of intragastric floating drug delivery.

Development and Optimisation of Novel Polymeric Compositions for Sustained Release Theophylline Caplets (PrintCap) via FDM 3D Printing

“…This type of composition can be used to produce a wide range of modified release drug delivery systems cost-effectively. Previous studies have successfully used HPC to produce Polymers 2020, 12, 27 4 of 18 drug-loaded filaments for the 3D printing of tablets [11,41,42]. However, HPC itself is hygroscopic, causing HPC-based filaments to have very short usage life [43].…”

“…This means the maximum efficiency of the drug can be obtained as the storage time is minimised and hence degradation can also be minimised [9]. Since the U.S. Food and Drug Administration's (FDA) approval of the first 3D printed drug, Spritram ® , there has been plenty of research that involves the 3D printing of various types of drug delivery systems [10][11][12]. The most easily accessible and low-cost 3D printing is fused deposition modelling (FDM).…”

Effect of Infill Percentage on Properties of FDM Printed GPLA/PETGs

“…Similarly, the specific strength of the GPLA is found to be 5.422 MPa and PETG to be 3.42MPa as shown in figure 11. From the observation it is found that the specific strength of GPLA with 15% infill is higher to that of PTEG resulting in enhanced properties of GPLA and PETG [16].…”

Current formulation approaches in design and development of solid oral dosage forms through three-dimensional printing

“…For instance, channelled tablets show an accelerated drug release due to the increased surface area to volume ratio [10], while a multi-block tablet design results in a quicker fragmentation compared to no-gaps devices, thus avoiding the need for a disintegrant [11]. A further example is altering tablet density by varying the infill percentage in fused deposition modelling (FDM) 3D printed tablets; as a result, different drug release profiles can be achieved without modifying the formulation [12,13]. The advantages of such approach are significative, since dosage forms tailored on the needs of single patients could be manufactured at a moment using the same equipment and feedstock material, with a positive outcome on treatments costs.…”